GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » FCF Yield %

SILO (SILO Pharma) FCF Yield % : -68.27 (As of Mar. 30, 2025)


View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, SILO Pharma's Trailing 12-Month Free Cash Flow is $-3.83 Mil, and Market Cap is $5.61 Mil. Therefore, SILO Pharma's FCF Yield % for today is -68.27%.

The historical rank and industry rank for SILO Pharma's FCF Yield % or its related term are showing as below:

SILO' s FCF Yield % Range Over the Past 10 Years
Min: -120.86   Med: -3.26   Max: 3.77
Current: -68.27


During the past 13 years, the highest FCF Yield % of SILO Pharma was 3.77%. The lowest was -120.86%. And the median was -3.26%.

SILO's FCF Yield % is ranked worse than
78.7% of 1502 companies
in the Biotechnology industry
Industry Median: -14.915 vs SILO: -68.27

SILO Pharma's FCF Margin % for the quarter that ended in Sep. 2024 was -7,483.33%.


SILO Pharma FCF Yield % Historical Data

The historical data trend for SILO Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SILO Pharma FCF Yield % Chart

SILO Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.61 -3.20 -16.20 -32.96 -77.04

SILO Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.59 -86.98 -60.68 -78.69 -109.24

Competitive Comparison of SILO Pharma's FCF Yield %

For the Biotechnology subindustry, SILO Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SILO Pharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where SILO Pharma's FCF Yield % falls into.


;
;

SILO Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

SILO Pharma's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-3.224 / 4.18464
=-77.04%

SILO Pharma's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.347 * 4 / 4.9324
=-109.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SILO Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


SILO Pharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of SILO Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


SILO Pharma Business Description

Traded in Other Exchanges
N/A
Address
677 N. Washington Boulevard, Sarasota, FL, USA, 34236
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Executives
Eric Weisblum director, officer: President and CCO 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz director 560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller director
Joel Alan Stone, director 1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps director C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand director, officer: Chairman and CEO 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd 10 percent owner P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats officer: VP of Business Development 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis director, officer: CFO 72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 72 POND ROAD, WOODBURY NY 11797